http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2676824-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37f4922dfb7777b019e504b885211b8e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d2e7fa9433e04fc27265b1d92b48e1d0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1870024223df71c715c62d0edd723acb |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-002 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-45 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-1088 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-002 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-45 |
| filingDate | 2013-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef39267447a90e430f66d7fbe041607f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1f0a842c02332da416f780ffb12cd876 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_448fa4492a3d7492786fe2f614f50966 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e13fb6c1a1bf29c0ea5d60a04b6ebf4c |
| publicationDate | 2018-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2676824-T3 |
| titleOfInvention | GST 28 KDa proteins that come from schistosomes for use in the treatment of autoimmune inflammatory diseases that generate a Th1 and / or Th17 type response |
| abstract | Product chosen from a protein, a fragment of said protein, a derived sequence and a homologous sequence of said protein, characterized in that: - said protein comprises or is constituted by the 28 KDa Glutathione S-transferase protein of a schistosome chosen from Schistosoma haematobium, Schistosoma mansoni, Schistosoma bovis respectively represented by the sequences SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3; - said fragment is a fragment of one of said proteins comprising, at least one region comprised between the following regions: the region comprised by the amino acid from position 15 to the amino acid at position 60, the region comprised by the amino acid from the position 20 to the amino acid at position 50, the region comprised by the amino acid from position 24 to the amino acid at position 43, the region comprised by the amino acid from position 170 to the amino acid at position 220, the region comprised by the amino acid of the position 180 to the amino acid at position 215, the region comprised by the amino acid from position 190 to the amino acid at position 211 of the sequence SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; this generating a Th2 type immune response, characterized by the production of IL-4, IL-5 or IL-13 by lymphocytes that do not produce gamma IFN; and this decreasing the Th1 type immune response, the Th1 type immune response being characterized by the production of gamma IFN and TNF by lymphocytes that do not produce IL-4 or IL-5, and the production of IL-1b by tissues rat colon; - said derived sequence is obtained from one of said sequences SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3 or one of said fragments mentioned above and is obtained in particular by deletion, substitution or addition of one or more amino acids, in the sequence SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3, said derived sequence comprising at least one region comprised between the following regions: the region comprised by the amino acid of position 15 to the amino acid at position 60, the region comprised by the amino acid from position 20 to the amino acid at position 50, the region comprised by the amino acid from position 24 to the amino acid at position 43, the region comprised by the amino acid from position 170 to the amino acid at position 220, the region comprised by the amino acid from position 180 to the amino acid at position 215 and the region comprised by the amino acid from position 190 to the amino acid at position tion 211 of the sequence SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; this inducing the generation of a Th2 response and / or the decrease of the Th1 response, characterized respectively by the production of IL-4, IL-5 or IL-13, and the production of gamma IFN, TNF or IL-1b; and - said homologous sequence is a homologous sequence of one of said sequences SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3 or one of said fragments, and has an identity of at least 80% or at least 85% with at least one of the following regions of said sequences: the region comprised by the amino acid from position 15 to the amino acid at position 60, the region comprised by the amino acid from position 20 to the amino acid at position 50 , the region comprised by the amino acid from position 24 to the amino acid at position 43, the region comprised by the amino acid from position 170 to the amino acid at position 220, the region comprised by the amino acid from position 180 to the amino acid at position 215, and the region comprised by the amino acid from position 190 to the amino acid at position 211 of the sequence SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; or with all of one of the sequences SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; this inducing the generation of a Th2 response and / or the decrease of the Th1 response, characterized respectively by the production of IL-4, IL-5 or IL-13, and the production of gamma IFN, TNF or IL-1b; for use in the preventive and / or curative treatment of a chronic inflammatory disease related to a deregulation of the immune system that generates an immune response of type Th1 and / or Th17 chosen among the autoimmune inflammatory diseases comprising Berger's disease, Basedow's disease Hashimoto's thyroiditis, primary myxedema, celiac disease, hemorrhagic rectocolitis, Crohn's disease, rheumatoid arthritis, primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hemolytic anemias, Biermer's anemia (pernicious anemia), lupus erythematosus, CREST syndrome, diabetes type 1, scleroderma, pemphigus vulgaris, bullous pemphigoid, acquired bullous epidermolysis, dermatitis herpetiformis, myasthenia, myasthenic Lambert-Eaton syndrome, polymyositis, Goujerot-Sjögren syndrome, plaque sclerosis, rheumatoid polyarthritis, psoriasis disease. |
| priorityDate | 2012-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 333.